<DOC>
	<DOCNO>NCT01534312</DOCNO>
	<brief_summary>Casein glycomacropeptide ( CGMP ) anti-inflammatory property experimental rodent colitis use human vitro inflammation model . Its use food ingredient proven safe influence dietary intake . We hypothesize orally administer CGMP beneficial effect comparable mesalazine active distal ulcerative colitis .</brief_summary>
	<brief_title>Casein Glycomacropeptide Active Distal Ulcerative Colitis ( Pilot Study )</brief_title>
	<detailed_description>GCMP mainly use food additive patient specific dietary need , i.e . infant formula , adipositas , patient phenylketonuria . Due antiinflammatory property hypothesize may use alone along conventional therapy inflammatory disease ulcerative colitis .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<mesh_term>Caseins</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>Age 18 year Diagnosed ulcerative colitis Signs clinical activity SCCAI 3 Extension 10 cm 40 cm anus Rectal temperature 38 degree Celcius Diagnosed celiac disease lactose intolerance Unable speak understand Danish Prior biologics systemic steroid 4 week inclusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Glycopeptides</keyword>
	<keyword>Dietary protein</keyword>
</DOC>